(Q46750806)

24 December 2017

title

Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial (English)

1 reference

24 December 2017

1 reference

1 reference

1

Julien Taieb

1 reference

24 December 2017

Pierre Laurent-Puig

series ordinal

2

object named as

Pierre Laurent Puig

1 reference

24 December 2017

author name string

Laurent Bedenne

series ordinal

3

1 reference

24 December 2017

publication date

1 February 2008

1 reference

24 December 2017

Expert Review of Anticancer Therapy

published in

1 reference

24 December 2017

volume

8

1 reference

24 December 2017

issue

2

1 reference

24 December 2017

page(s)

183-189

1 reference

24 December 2017

(Neo-)adjuvant treatments in colorectal cancer.

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.183

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.183

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.183

Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.183

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.183

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.183

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.183

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.183

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.183

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.183

Cetuximab therapy and symptomatic hypomagnesemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.183

Cancer incidence and mortality in Europe, 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.183

21 January 2018

Identifiers

DOI

10.1586/14737140.8.2.183

1 reference

24 December 2017

1 reference

24 December 2017